Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Continues Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Capricor Therapeutics, --> Accessibility: Skip TopNav Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Continues Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz July 30, 2026 17:14 ET | Source: The Law Offices of Frank R. Cruz The Law Offices of Frank R. Cruz LOS ANGELES, July 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR ) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 27, 2026, the US Food and Drug Administration released briefing documents ahead of its advisory committee meeting with Capricor regarding deramiocel, the Company's cell ​therapy for a heart condition related to Duchenne muscular dystrophy. Among other things, the briefing documents take issue with the manner in which Capricor measured results after the therapy's late-stage trial ended, stating the " FDA does not ​consider the conversion of raw change to percent change and then back to raw change ​to have been scientifically justified , as it adds complexity and reduces accuracy." The briefing documents conclude that, among other things, "the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness." Cantor Fitzgerald analyst Kristen Kluska published an investor note on the issue, stating the FDA’s “briefing documents paint an ugly picture” and “ raise several concerns and make allegations about the integrity of data collecting .” On this news, shares of Capricor stock declined $12.70 or 64.5%, to close at $7.00 on July 27, 2026, thereby injuring investors. Then, on July 29, 2026, the FDA held Tissue, and Gene Therapies Advisory Committee meeting review of deramiocel. On this news, shares of Capricor stock fell $0.42 or 6.08%, to close at $6.57 on July 29, 2026, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased Capricor securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: [email protected] Visit our website at: www.frankcruzlaw.com . Follow us for updates on Twitter at twitter.com/FRC_LAW . If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz 310-914-5007 [email protected] www.frankcruzlaw.com Tags Class Action GlobeNewswire Recommended Reading July 30, 2026 17:15 ET | Source: The Law Offices of Frank R. Cruz Securities Fraud Investigation Into HDFC Bank Limited (HDB) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, July 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of HDFC Bank Limited (“HDFC Bank” or the “Company”) (NYSE: HDB) on behalf of investors... Read More July 30, 2026 12:09 ET | Source: The Law Offices of Frank R. Cruz DEADLINE ALERT for INTU, PLNT, and GPGI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders LOS ANGELES, July 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following... Read More